Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
The DOI matches its Crossref record.
Abstract
Semisynthetic homoharringtonine (ssHHT) is now being evaluated in phase II clinical trials for the treatment of chronic myelogenous leukemia and acute myelogenous leukemia patients. Here, we examined the mechanism of the apoptosis induced by ssHHT in myeloid leukemia cells. First, we have shown that ssHHT induces apoptosis in HL60 and HL60/MRP cell lines in a time- and dose-dependent manner, and independently of the expression of Bax. The decrease of mitochondrial membrane potential and the release of cytochrome c were observed in the apoptotic cells induced by ssHHT. To unveil the relationship between ssHHT and the mitochondrial disruption, we have shown that ssHHT decreased myeloid cell leukemia-1 (Mcl-1) expression and induced Bcl-2 cleavage in HL60 and HL60/MRP cell lines. The Bcl-2 cleavage could be inhibited by the Z-VAD.fmk caspase inhibitor. However, Mcl-1 turnover was very rapid and occurred before caspase activation. The Mcl-1 turnover was only induced by ssHHT and cycloheximide, but not by daunorubicin and cytosine arabinoside, and could be restored by proteasome inhibitors. Second, we confirmed that ssHHT rapidly induced massive apoptosis in acute myelogenous leukemia patient cells. We have also confirmed the release of cytochrome c and a rapid turnover of Mcl-1 in these patient cells, taking place only in apoptotic cells induced by ssHHT but not in cells undergoing spontaneous apoptosis. Finally, we have shown that ssHHT inhibits protein synthesis in both cell line and patient cells. We suggest that the inhibition of protein synthesis and resulting Mcl-1 turnover play a key role in the apoptosis induced by ssHHT. Our results encourage further clinical trials for the use of ssHHT in acute myelogenous leukemia. [Mol Cancer Ther 2006;5(3):723–31]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The impact of the unfolded protein response on human disease
Wang, S., & Kaufman, R. J. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201110131 · Cited by 984
GRP78 Induction in Cancer: Therapeutic and Prognostic Implications
Lee, A. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0325 · Cited by 856
Dong, D., Ni, M., Li, J., Xiong, S., Ye, W., Virrey, J. J., Mao, C., Ye, R., Wang, M., Pen, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2950 · Cited by 375
Mcl-1 is a potential therapeutic target in multiple types of cancer
Akgul, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8637-6 · Cited by 329
ATF4 is an oxidative stress–inducible, prodeath transcription factor in neurons in vitro and in vivo
Lange, P. S., Chavez, J. C., Pinto, J. T., Coppola, G., Sun, C.-W., Townes, T. M., Geschwind, D. H., & Ratan, R. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071460 · Cited by 272
Metadata
- Authors
- Tang, R., Faussat, A.-M., Majdak, P., Marzac, C., Dubrulle, S., Marjanovic, Z., Legrand, O., & Marie, J.-P.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2006-03-01
- Volume
- 5
- Issue
- 3
- Pages
- 723-731
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2139226937
- Cited by
- 151
- References
- 0
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. https://app.cochat.ai/papers/10.1158/1535-7163.mct-05-0164
- The paper
- Tang, R., Faussat, A.-M., Majdak, P., Marzac, C., Dubrulle, S., Marjanovic, Z., Legrand, O., & Marie, J.-P. (2006). Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-05-0164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.